Endocrinology News

Polycystic ovary syndrome presents in many forms with many manifestations, which is why providers must work with patients to treat the condition while factoring in their preferences and top concerns.

Circulating levels of some microRNA species may predict response to diabetes treatment and changes in beta-cell function among children and adolescents with type 2 diabetes, according to findings from the TODAY study.

Bloomberg Philanthropies announced that it has donated $1 billion to make Johns Hopkins University’s medical school free for most of its students seeking an MD.

More than one in five adults in the U.S. with type 1 diabetes also have chronic kidney disease, according to findings from a brief report published in Diabetes Care.

In a Healio exclusive, Andres J. Acosta, MD, PhD, highlights data demonstrating that the MyPhenome test may serve as a biomarker to determine whether a patient with obesity will be a “good responder” to semaglutide.

Adults with overweight or obesity lost more weight with the GIP/GLP-1 dual agonist tirzepatide than the GLP-1 receptor agonist semaglutide, according to findings published in JAMA Internal Medicine.

Lack of available health care providers, health insurance exclusions and a lengthy assessment process are among barriers transgender people face when seeking gender-affirming hormone therapy, according to study findings.

Like many sports, such as soccer and basketball, financial independence requires simultaneous offense and defense. One of the most important defensive plays a physician must make is buying disability insurance.

People with type 2 diabetes who use a GLP-1 receptor agonist have a lower risk for 10 types of obesity-associated cancer compared with those who use insulin, according to data published in JAMA Network Open.

Adults with diabetes or obesity using semaglutide may have an increased risk for nonarteritic anterior ischemic optic neuropathy, a common form of optic neuropathy, according to data published in JAMA Ophthalmology.